Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapropterin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAH known ✓ | P00439 | 1/20 | 0.81 |
| ▸ | NOS1 | P29475 | 10/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | NOS3 | P29474 | 3/20 | 0.62 |
| ▸ | NOS2 | P35228 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapropterin SCHEMBL21068033 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL4217501 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL29538547 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL29351671 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL29059706 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL14072498 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL260185 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL14401407 | 1.00 | NOS1 (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL31106620 | 0.99 | KDM4E (1.00) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL1070424 | 0.99 | KDM4E (1.00) | NOS1CASP7HSD17B10USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220268782-A1 | METHODS FOR PREDICTING AND TREATING CARDIAC DYSFUNCTION | INSERM INSTITUT NATIONAL DE LA SANTE EAT DE LA RECH MEDICALE (FR) | 2022-08-25 | — | — | US | disclosed |
| EP-3999071-A1 | METHODS FOR PREDICTING AND TREATING CARDIAC DYSFUNCTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-05-25 | — | — | EP | disclosed |
| EP-3977999-A1 | TREATMENT OF PHENYLKETONURIA WITH BH4 | BioMarin Pharmaceutical Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10738335-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190144900-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2019-05-16 | — | — | US | disclosed |
| EP-2309983-B1 | PHARMACEUTICAL FORM COMPRISING TETRAHYDROBIOPTERIN | ORPHA SWISS GMBH (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20170042899-A1 | Use of Tetrahydrobiopterine Derivatives in the Treatment and Nutrition of Patients With Amino Acid Metabolic Disorders | BIOMARIN PHARM INC (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170042899-A1 | Use of Tetrahydrobiopterine Derivatives in the Treatment and Nutrition of Patients With Amino Acid Metabolic Disorders | BIOMARIN PHARM INC (US) | 2017-02-16 | — | — | US | disclosed |
| US-20160251691-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Nitrogen-Containing Compound And Uses Thereof | NOVOZYMES INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-9353391-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a nitrogen-containing compound and uses thereof | NOVOZYMES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | ORPHA SWISS GMBH (CH) | 2011-06-16 | — | — | US | disclosed |
| US-7820667-B2 | Methods of treating hypertension | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820667-B2 | Methods of treating hypertension | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| WO-2010017570-A2 | PHARMACEUTICAL FORM COMPRISING TETRAHYDROBIOPTERIN | ORPHA SWISS GMBH (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | NYCOMED GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | NYCOMED GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20070049599-A1 | Use of bh4 for the treatment of respiratory diseases | ALTANA PHARMA AG (DE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049599-A1 | Use of bh4 for the treatment of respiratory diseases | ALTANA PHARMA AG (DE) | 2007-03-01 | — | — | US | disclosed |
| WO-2006120176-A2 | COMBINATION OF THE PDE4 INHIBITOR ROFLUMILAST AND A TETRAHYDROBIOPTERIN DERIVATIVE | NYCOMED GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
| WO-2005041975-A1 | USE OF BH4 FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049599-A1 | Use of bh4 for the treatment of respiratory diseases | BHMT, BHMT2, PAH | PAH 3/4885NOS1 233/4885CASP7 3145/4885 |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | SPR, PAH, QDPR | PAH 2/4885NOS1 264/4885CASP7 1166/4885 |
| US-20170042899-A1 | Use of Tetrahydrobiopterine Derivatives in the Treatment and Nutrition of Patients With Amino Acid Metabolic Disorders | PAH, AADAT, BCAT1 | PAH 1/4885NOS1 545/4885CASP7 4674/4885 |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | QDPR, MTHFD2, DHODH | PAH 18/4885NOS1 611/4885CASP7 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.